Home / Business and Economy / BDX Stock Surges Past Market as Q3 Earnings Beat
BDX Stock Surges Past Market as Q3 Earnings Beat
19 Aug
Summary
- BDX stock has gained 19.6% in the past year, trailing the S&P 500.
- In 2026, BDX stock is up 20.2%, surpassing the S&P 500's 13.7% YTD rise.
- Q3 adjusted EPS of $3.23 beat expectations; revenue of $5 billion exceeded forecasts.
Becton, Dickinson and Company (BDX), a global medical technology firm, has seen its stock significantly outperform the S&P 500 on a year-to-date basis in 2026, with a 20.2% gain compared to the index's 13.7%. This recent success contrasts with its performance over the past year, where it gained 19.6% against the S&P 500's 20.4%.
The company's stock trajectory has been influenced by both past operational headwinds and recent recovery drivers. Lingering issues such as modest revenue growth and margin pressures had previously hampered its performance relative to peers. However, robust expansion in core areas, particularly drug delivery devices like GLP-1 auto-injectors, has revitalized investor sentiment.
BDX recently reported Q3 results on August 6, with its shares closing up 3.8%. The company announced adjusted earnings per share (EPS) of $3.23, surpassing analyst expectations of $3.14. Revenue for the quarter reached $5 billion, exceeding the consensus forecast of $4.9 billion. For the full fiscal year, BDX anticipates adjusted EPS between $12.62 and $12.72.
Analysts forecast BDX's diluted EPS for the current fiscal year to be $12.67, a 12% decrease. Despite this projection, the company has a strong track record of exceeding earnings estimates, having beaten the consensus in each of the last four quarters. Currently, 16 analysts cover BDX stock, with the consensus rating being a "Moderate Buy."
